Stifel Nicolaus Has Lowered Expectations for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT) had its price objective cut by Stifel Nicolaus from $10.00 to $5.00 in a research note published on Thursday morning,Benzinga reports. They currently have a hold rating on the stock.

A number of other equities research analysts also recently issued reports on HCAT. Canaccord Genuity Group lowered their target price on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 21st. Stephens restated an “equal weight” rating and issued a $7.00 target price on shares of Health Catalyst in a report on Thursday. Piper Sandler lowered their target price on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 11th. Royal Bank of Canada lowered their target price on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a report on Wednesday, January 15th. Finally, Citigroup lowered their target price on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a report on Friday, January 10th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.45.

Health Catalyst Price Performance

Health Catalyst stock opened at $4.67 on Thursday. Health Catalyst has a 1 year low of $3.76 and a 1 year high of $9.24. The firm has a 50 day moving average price of $5.98 and a 200 day moving average price of $7.24. The company has a market cap of $284.16 million, a price-to-earnings ratio of -3.46 and a beta of 1.34. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41.

Insider Activity

In other news, insider Linda Llewelyn sold 6,441 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $5.43, for a total value of $34,974.63. Following the completion of the transaction, the insider now directly owns 85,819 shares in the company, valued at approximately $465,997.17. This represents a 6.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Duncan Gallagher sold 4,500 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $6.98, for a total transaction of $31,410.00. Following the completion of the transaction, the director now owns 74,438 shares of the company’s stock, valued at $519,577.24. This trade represents a 5.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 87,610 shares of company stock worth $664,043. 2.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Harbor Capital Advisors Inc. boosted its stake in shares of Health Catalyst by 21.3% in the third quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock valued at $96,000 after purchasing an additional 2,064 shares during the period. Group One Trading LLC raised its holdings in Health Catalyst by 107.6% in the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock valued at $31,000 after acquiring an additional 2,260 shares in the last quarter. Creative Planning raised its holdings in Health Catalyst by 13.2% in the third quarter. Creative Planning now owns 21,348 shares of the company’s stock valued at $174,000 after acquiring an additional 2,486 shares in the last quarter. Two Sigma Securities LLC raised its holdings in Health Catalyst by 19.5% in the fourth quarter. Two Sigma Securities LLC now owns 17,510 shares of the company’s stock valued at $124,000 after acquiring an additional 2,862 shares in the last quarter. Finally, Legato Capital Management LLC raised its holdings in Health Catalyst by 3.7% in the fourth quarter. Legato Capital Management LLC now owns 87,992 shares of the company’s stock valued at $622,000 after acquiring an additional 3,171 shares in the last quarter. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.